Suppr超能文献

炎症性肠病孕妇的药物安全性和不良结局风险。

Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease.

机构信息

Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Francisco, California.

Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Francisco, California.

出版信息

Gastroenterology. 2017 Feb;152(2):451-462.e2. doi: 10.1053/j.gastro.2016.10.013. Epub 2016 Oct 18.

Abstract

The management of the pregnant patient with inflammatory bowel disease is complicated by multiple providers, misinformation, and a disease entity that, particularly when active, can adversely affect pregnancy outcomes. This article seeks to frame the debate on medication safety in pregnancy and lactation using the US Food and Drug Administration's new Pregnancy and Lactation Labeling Rule and the most up-to-date safety information to discuss the risks and benefits of using each class of inflammatory bowel disease medication.

摘要

炎症性肠病孕妇的管理涉及多个医疗服务提供者、错误信息以及一种疾病实体,特别是在疾病活跃期时,可能对妊娠结局产生不利影响。本文旨在利用美国食品和药物管理局(FDA)新的妊娠和哺乳期标签规则以及最新的安全性信息,讨论每一类炎症性肠病药物的风险和获益,以此来构建妊娠期和哺乳期用药安全性的相关争议。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验